<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89103">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01991652</url>
  </required_header>
  <id_info>
    <org_study_id>CollabWilmsAfrica</org_study_id>
    <nct_id>NCT01991652</nct_id>
  </id_info>
  <brief_title>Collaborative Wilms Tumour Africa Project</brief_title>
  <official_title>Collaborative Wilms Tumour Africa Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VU University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Society of Pediatric Oncology (SIOP)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>VU University Medical Center</source>
  <oversight_info>
    <authority>Malawi: College of Medicine Research and Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Significant progress has been made in the treatment of Wilms tumor in high income countries,
      where survival is now around 85% - 90%. Survival in low income countries is much lower;
      specific challenges include late presentation, malnutrition, less intense supportive care
      facilities and failure to complete treatment.

      A comprehensive treatment guideline was introduced in Malawi in 2006 which included
      nutritional support and social support to enable parents to complete treatment. Survival has
      increased to around 50%; 95% of children completed their treatment. A multi-disciplinary
      group of African clinicians and 'state of the art' experts produced a consensus treatment
      guideline for children with Wilms tumor in sub-Saharan Africa. This guideline will be
      implemented as a multi-center prospective clinical trial in 2014 in six - eight institutes,
      expecting about 200 new patients per year.

      The hypothesis is that 2 year event free survival will be 50%, with &lt;10% failure to complete
      treatment and &lt;10% treatment related mortality. Other research questions include efficacy
      and toxicity of preoperative chemotherapy and the comparison of surgical staging, local
      pathology and central review pathology in stratifying postoperative chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Event free survival</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Wilms Tumour</condition>
  <arm_group>
    <arm_group_label>Wilms tumour</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children diagnosed with a Wilms tumour receive SIOP PODC Wilms tumour treatment; preoperative chemotherapy, surgery and postoperative chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SIOP PODC Wilms tumour treatment: Preoperative chemotherapy</intervention_name>
    <arm_group_label>Wilms tumour</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SIOP PODC Wilms tumour treatment: surgery</intervention_name>
    <arm_group_label>Wilms tumour</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SIOP PODC Wilms tumour treatment: post operative chemotherapy</intervention_name>
    <arm_group_label>Wilms tumour</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &lt; 18 years

          -  Diagnosis Wilms tumour

        Exclusion Criteria:

        * None
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Trijn Israels, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>VU University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trijn Israels, MD PhD</last_name>
    <phone>+31.6.42717920</phone>
    <email>t.israels@vumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth Molyneux, Prof</last_name>
    <email>emmolyneux@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mbingo Mission Hospital</name>
      <address>
        <city>North West Cameroon</city>
        <country>Cameroon</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Hesseling</last_name>
      <email>pbh@sun.ac.za</email>
    </contact>
    <investigator>
      <last_name>Francine Kouya, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tikur Anbessa Specialized Hospital</name>
      <address>
        <city>Addis Abeba</city>
        <country>Ethiopia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yasar Celiker, MD</last_name>
      <email>myceliker@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Yasar Celiker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korle Bu Hospital</name>
      <address>
        <city>Accra</city>
        <country>Ghana</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lorna Renner, MD</last_name>
      <email>lornarenner@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Lorna Renner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>College of Medicine</name>
      <address>
        <city>Blantyre</city>
        <country>Malawi</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elizabeth Molyneux, Prof</last_name>
      <email>emmolyneux@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Neil Kennedy, Prof</last_name>
      <email>n.kennedy@medcol.mw</email>
    </contact_backup>
    <investigator>
      <last_name>Elizabeth Molyneux, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Muhimbili Hospital</name>
      <address>
        <city>Dar es Salaam</city>
        <country>Tanzania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Trish Scanlan, MD</last_name>
      <email>trishascan@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Lulu Chirande, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Kampala</city>
        <country>Uganda</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jackson Orem, Prof</last_name>
      <email>jacksonorem@yahoo.co.uk</email>
    </contact>
    <investigator>
      <last_name>Joyce Balagadde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Cameroon</country>
    <country>Ethiopia</country>
    <country>Ghana</country>
    <country>Malawi</country>
    <country>Tanzania</country>
    <country>Uganda</country>
  </location_countries>
  <reference>
    <citation>Israels T, Moreira C, Scanlan T, Molyneux L, Kampondeni S, Hesseling P, Heij H, Borgstein E, Vujanic G, Pritchard-Jones K, Hadley L. SIOP PODC: clinical guidelines for the management of children with Wilms tumour in a low income setting. Pediatr Blood Cancer. 2013 Jan;60(1):5-11. doi: 10.1002/pbc.24321. Epub 2012 Sep 26.</citation>
    <PMID>23015404</PMID>
  </reference>
  <reference>
    <citation>Israels T, Renner L, Hendricks M, Hesseling P, Howard S, Molyneux E; Paediatric Oncology in Developing Countries. SIOP PODC: recommendations for supportive care of children with cancer in a low-income setting. Pediatr Blood Cancer. 2013 Jun;60(6):899-904. doi: 10.1002/pbc.24501. Epub 2013 Feb 25. PubMed PMID: 23441092.</citation>
    <PMID>23441092</PMID>
  </reference>
  <reference>
    <citation>IsraÃ«ls T, Kambugu J, Kouya F, El-Mallawany NK, Hesseling PB, Kaspers GJ, Eden T, Renner L, Molyneux EM. Clinical trials to improve childhood cancer care and survival in sub-Saharan Africa. Nat Rev Clin Oncol. 2013 Oct;10(10):599-604. doi: 10.1038/nrclinonc.2013.137. Epub 2013 Jul 30.</citation>
    <PMID>23897077</PMID>
  </reference>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 21, 2013</lastchanged_date>
  <firstreceived_date>November 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>VU University Medical Center</investigator_affiliation>
    <investigator_full_name>Trijn Israels</investigator_full_name>
    <investigator_title>Paediatric Oncologist, MD PhD</investigator_title>
  </responsible_party>
  <keyword>Wilms tumour</keyword>
  <keyword>Childhood cancer</keyword>
  <keyword>Africa</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Wilms Tumor</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
